Cybin Expands Their Patent Portfolio | Trade To Black скачать в хорошем качестве

Cybin Expands Their Patent Portfolio | Trade To Black

It’s been a long journey, but Cybin Inc. (NEO: CYBN) (OTCMKTS: CLXPF) is making strides towards filing its first Investigational New Drug (IND) application with the FDA. Leading up to this milestone event, TDR Founder Shadd Dales caught up with CEO Doug Drysdale this past week at the Benzinga Cannabis Capital Conference in Miami. The topics of conversation the company’s clinical trial roadmap, the booming need for improved anxiety therapeutics, the state of psychedelic markets and more. Cybin’s leading drug investigational compound, CYB004, is a proprietary DMT compound. In preclinical studies, CYB004 has demonstrated potential efficacy at lower doses while also increasing the duration of drug effect—while possibly alleviating common negative experiences associated with classical DMT. The company will pursue social anxiety disorder and generalized anxiety disorder as the initial target indications for CYB004. To view our previous Trade To Black Podcast 36, click here:    • Why Is Cannabis Being Delayed | Trade To B...   __________________________________________________________ Timestamps: 0:00 Intro 0:56 CYB004 Could Be Getting Into The Clinic In The Not-Too-Distant Future 1:27 Cybin Will Soon Be Filing Its First IND With The FDA - This Is 18 Months Of Work 1:56 How Long Is The Timeline To Review The IND Process 2:28 Understanding CYB004 For Anxiety Disorder 3:17 Getting A Better Education As To Why CYB004 Is Cybin's Lead Candidate 4:14 What Doug Drysdale Is Hearing As Far As Sharing Information On The Overall Growth Of The Industry 6:07 The Practical Use Of These Treatments And What's The Whole Process Going To Be Like 7:37 Drysdale Is Exploring Things As Far As Mergers And Acquisition Topic Within The Industry 9:17 The industry Overall Stock Performance In Doug's Opinion 10:44 Hopes For Biotech Industry 11:41 Tony Robbins As Shareholder Investor Of The Company 12:45 Cybin Expects To Initiate A Phase 2 And Biotech Stocks In The Next 6 to 12 Months Or So 14:07 Finalizing __________________________________________________________ About Channel: We are a business news platform that provides the latest and best insight on the stories making headlines around the world. We give Institutional and retail investors an inside edge in the competitive world of investing and profile companies that are making waves in their ever-growing industries. We are The Dales Report. Check out our website: https://thedalesreport.com/​​ Subscribe to our channel at https://article.thedalesreport.com/yo... Connect with us on our social media handles: Twitter:   / thedalesreport​​   Instagram:   / thedalesrep...​   Tiktok:   / thedalesrepor...​   Facebook:   / thedalesreport​   TDR Contributors Instagram: Nicolle Hodges:   / nicolledoublel   Anthony Varrell:   / anthonyvarrell   _________________________________________________ The Dales Report Inc. disclosure policy applies to this video: https://thedalesreport.com/disclosure/